Philip Kuball, MD

Articles by Philip Kuball, MD

Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MD

ByPhilip Kuball, MD,Luke Halpern,Isabella Ciccone, MPH

April 18th 2025

The resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]

Latest Updated Articles

FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease
Published: August 29th 2025 | Updated: September 2nd 2025
Indirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over Donanemab
Published: July 28th 2025 | Updated: July 30th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on Term
Published: May 14th 2025 | Updated: May 16th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack Severity
Published: May 12th 2025 | Updated: May 13th 2025
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
Published: March 4th 2025 | Updated: March 19th 2025

Philip Kuball, MD

Articles by Philip Kuball, MD

Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MD

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity

Insights Into the Neurobiology of Stuttering From 2025 STARS Conference: Shahriar SheikhBahaei, PhD

Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition

EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits

Optimizing Speech and Movement Therapy to Improve Motor and Nonmotor Symptoms of Parkinson Disease: Cynthia Fox, PhD, CCC-SLP